VIR vs. MOR, KYMR, IMVT, CRNX, ALVO, HCM, AMRX, CPRX, BHC, and OGN
Should you be buying Vir Biotechnology stock or one of its competitors? The main competitors of Vir Biotechnology include MorphoSys (MOR), Kymera Therapeutics (KYMR), Immunovant (IMVT), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), HUTCHMED (HCM), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), Bausch Health Cos (BHC), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry.
Vir Biotechnology vs. Its Competitors
Vir Biotechnology (NASDAQ:VIR) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.
MorphoSys has higher revenue and earnings than Vir Biotechnology. MorphoSys is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 16.0% of Vir Biotechnology shares are held by insiders. Comparatively, 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
MorphoSys has a net margin of -226.79% compared to Vir Biotechnology's net margin of -2,769.04%. Vir Biotechnology's return on equity of -47.46% beat MorphoSys' return on equity.
Vir Biotechnology presently has a consensus target price of $32.86, indicating a potential upside of 519.95%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, equities analysts clearly believe Vir Biotechnology is more favorable than MorphoSys.
Vir Biotechnology has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.
In the previous week, Vir Biotechnology had 3 more articles in the media than MorphoSys. MarketBeat recorded 4 mentions for Vir Biotechnology and 1 mentions for MorphoSys. Vir Biotechnology's average media sentiment score of 0.74 beat MorphoSys' score of -0.71 indicating that Vir Biotechnology is being referred to more favorably in the media.
Summary
Vir Biotechnology beats MorphoSys on 10 of the 16 factors compared between the two stocks.
Get Vir Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vir Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:VIR) was last updated on 7/9/2025 by MarketBeat.com Staff
Free VIR Stock Alerts